Jove
Visualize
Contact Us

Related Concept Videos

Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Addressing Gaps in Parkinson's Disease Etiology: The Need for a Polyexposure Score.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Effect on Dyskinesia of the Early Combination of Amantadine to Levodopa-Therapy in Parkinson's Disease: A Randomized, Placebo-Controlled Study (PREMANDYSK).

Movement disorders : official journal of the Movement Disorder Society·2025
Same author

In Memoriam C. Warren Olanow (1941-2024).

Movement disorders clinical practice·2025
Same author

Brain network connectivity underlying neuropsychiatric symptoms in prodromal Lewy body dementia.

Neurobiology of aging·2025
Same author

In Memoriam C. Warren Olanow (1941-2024).

Movement disorders clinical practice·2025
Same author

In Memoriam C. Warren Olanow (1941-2024).

Movement disorders : official journal of the Movement Disorder Society·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 13, 2026

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

Parkinson's disease dementia.

Mary J Docherty1, David J Burn

  • 1Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne, UK.

Current Neurology and Neuroscience Reports
|April 30, 2010
PubMed
Summary

Parkinson's disease dementia (PDD) causes significant health issues. Current treatments are insufficient, highlighting the need for new disease-modifying therapies to effectively combat PDD.

Area of Science:

  • Neurodegenerative diseases
  • Neurology
  • Geriatrics

Background:

  • Parkinson's disease dementia (PDD) presents a substantial clinical challenge, contributing significantly to patient morbidity and mortality.
  • Despite increased research focus over the last decade, critical knowledge gaps persist regarding PDD's underlying mechanisms.
  • Existing therapeutic strategies have yielded limited success in altering the disease's trajectory.

Purpose of the Study:

  • To review the current understanding of Parkinson's disease dementia (PDD).
  • To identify key knowledge gaps hindering therapeutic advancements.
  • To emphasize the need for novel therapeutic approaches for PDD.

Main Methods:

  • Literature review of recent research on PDD.
  • Analysis of current therapeutic strategies and their limitations.

More Related Videos

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

Related Experiment Videos

Last Updated: Jun 13, 2026

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

  • Identification of areas requiring further investigation.
  • Main Results:

    • PDD is a prevalent and serious complication of Parkinson's disease.
    • Significant gaps in fundamental knowledge about PDD remain.
    • Current treatments primarily focus on symptom management, not disease modification.

    Conclusions:

    • Novel "disease-modifying" agents are essential for substantial impact on PDD.
    • Traditional neurotransmitter replacement therapies are insufficient for long-term PDD management.
    • Future research should prioritize developing therapies that target the underlying pathology of PDD.